OverviewSuggest Edit

Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. The Company has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes.

TypePublic
Founded2011
HQSouth San Francisco, US
Websiteatreca.com
Employee Ratings4.5

Latest Updates

Employees (est.) (Sept 2019)102(+4%)
Job Openings13
Share Price (Aug 2020)$13.3 (+4%)
Cybersecurity ratingAMore

Key People/Management at Atreca

John Orwin

John Orwin

President and CEO
Guy Cavet

Guy Cavet

Chief Technology Officer
Jonathan Benjamin

Jonathan Benjamin

Vice President, Clinical Research
Paulette Dillon

Paulette Dillon

Senior Vice President of Corporate Development and Co-Founder
Lisa Decker

Lisa Decker

Chief Business Officer
Daniel Emerling

Daniel Emerling

Sr. Vice President, Research
Show more

Atreca Office Locations

Atreca has an office in South San Francisco
South San Francisco, US (HQ)
450 E Jamie Ct
Show all (1)

Atreca Financials and Metrics

Atreca Revenue

USD

Net income (Q1, 2020)

(20.4m)

Market capitalization (30-Jul-2020)

499.9m

Closing stock price (30-Jul-2020)

13.2

Cash (31-Mar-2020)

92.2m

EV

407.8m
Atreca's current market capitalization is $499.9 m.
Annual
USDFY, 2017FY, 2018FY, 2019

General and administrative expense

4.6m7.1m17.8m

R&D expense

24.9m32.5m54.7m

Operating expense total

29.4m39.6m72.6m

EBIT

(29.4m)(39.6m)
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020

General and administrative expense

3.5m4.9m7.1m

R&D expense

15.9m12.8m14.2m

Operating expense total

19.5m17.7m21.3m

Interest expense

2.0k1.0k
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

8.2m114.5m158.0m

Prepaid Expenses

1.4m2.7m3.5m

Current Assets

32.0m117.2m176.1m

PP&E

3.8m4.1m5.8m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020

Cash

155.0m166.1m92.2m

Prepaid Expenses

2.6m5.4m3.1m

Current Assets

222.3m206.5m154.2m

PP&E

4.2m4.7m6.6m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(27.5m)(37.9m)(67.5m)

Depreciation and Amortization

1.2m1.4m1.7m

Accounts Payable

136.0k698.0k826.0k

Cash From Operating Activities

(25.1m)(34.7m)(58.5m)
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020

Net Income

(31.5m)(47.4m)(20.4m)

Depreciation and Amortization

792.0k1.2m541.0k

Accounts Payable

1.9m1.5m(79.0k)

Cash From Operating Activities

(26.7m)(42.3m)(17.9m)
USDFY, 2017

Financial Leverage

-0.6 x
Show all financial metrics

Atreca Acquisitions / Subsidiaries

Company NameDateDeal Size
Atreca Pte. Ltd.

Atreca Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Atreca Online and Social Media Presence

Embed Graph

Atreca News and Updates

Atreca, Inc. Announces Pricing of Underwritten Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced the pricing of its pr…

Atreca Reports Fourth Quarter and Full Year 2019 Financial Results

SOUTH SAN FRANCISCO, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today anno…

Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel

REDWOOD CITY, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the appointment of Lisa L. Decker, Ph.D., as Chief Business Officer and …

Atreca looks to raise up to $132.3 million in IPO

Atreca Inc. has set terms for its initial public offering, as the biopharmaceutical company developing tumor treatments aims to raise up go $132.3 million. Redwood City, Calif.-based Atreca disclosed Monday that it was offering 7.35 million shares in the IPO, which is expected to price between $16 …

Atreca Frequently Asked Questions

  • When was Atreca founded?

    Atreca was founded in 2011.

  • Who are Atreca key executives?

    Atreca's key executives are John Orwin, Guy Cavet and Jonathan Benjamin.

  • How many employees does Atreca have?

    Atreca has 102 employees.

  • Who are Atreca competitors?

    Competitors of Atreca include React4life, Calbiotech and Scaffdex.

  • Where is Atreca headquarters?

    Atreca headquarters is located at 450 E Jamie Ct, South San Francisco.

  • Where are Atreca offices?

    Atreca has an office in South San Francisco.

  • How many offices does Atreca have?

    Atreca has 1 office.